ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2851

Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations

Nina Sundlisater1, Anna-Birgitte Aga 2, Ulf Sundin 3, Hilde Hammer 1, Till Uhlig 4, Tore Kvien 4, Espen Haavardsholm 4 and Siri Lillegraven 5, 1Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, 3Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway. University of Oslo, Oslo, Norway, Oslo, Oslo, Norway, 4Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 5Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Early Rheumatoid Arthritis, outcome measures and ultrasonography, remission

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: 5T114: RA – Diagnosis, Manifestations, & Outcomes IV: Outcomes (2846–2851)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission criteria have the most stringent remission definition.(1) It has been reported that patient global assessment (PGA) is the variable most commonly scored above the cut-off in patients who almost fulfill the ACR/EULAR Boolean remission criteria.(2) Our objective was to assess which components of the ACR/EULAR Boolean criteria that most often limit attainment of remission in modernly treated early RA, and quantify the extent of subclinical inflammation in these patients.

Methods: DMARD-naïve early RA patients included in the treat-to-target ARCTIC trial were followed by a strict tight control regime aiming for DAS remission and no swollen joints, with an additional target of ultrasound remission in half of the patients.(3) Examination of all patients included 44SJC, Ritchie articular index (RAI), laboratory tests, patient reported outcomes included physical function (PROMIS), ultrasound (US) of 32 joints and magnetic resonance imaging (MRI) of the dominant hand and wrist (scored according to RAMRIS). Patients with complete clinical data at the 2-year follow-up visit were included in the current analyses. We assessed the proportion of patients fulfilling ACR/EULAR Boolean remission (based on 44 joints) and the proportion of patients fulfilling three out of four remission criteria, and in such cases, which were the limiting factors. We compared physical function and imaging inflammation (assessed by US power Doppler score, US grey scale score, MRI synovitis and bone marrow edema) in patients reaching complete ACR/EULAR Boolean remission to patients not reaching ACR/EULAR Boolean remission due to the most often limiting factors. Chi2 test and Wilcoxon rank sum test were used for the comparisons.

Results: Of the 203 patients included, 62% were females, mean (SD) age was 52 (13) years, and 81% were ACPA positive. ACR/EULAR Boolean remission was achieved by 112 of 203 patients after 24 months (55%), while 49 (24%) fulfilled three of the four remission criteria. Among these 49 patients, the major limiting factor for not reaching remission was PGA (n=29, 59%), with tender joints as the second most common limiting factor (n=11, 22%) (Figure). In patients not achieving remission due to PGA, the median [IQR] PGA value was 3.1 [2, 4.4]. Subclinical inflammation measured by ultrasound and MRI was not significantly different for patients in ACR/EULAR Boolean remission compared to patients not fulfilling these criteria due to PGA  and /or tender joints  (Table), but the latter reported more subjective symptoms such as fatigue and impaired physical function.

Conclusion: PGA and tender joints are the variables most often limiting patients from achieving ACR/EULAR Boolean remission, also in a treat-to-target setting with high remission rates. The level of subclinical inflammation is not elevated in these patients compared to patients in ACR/EULAR Boolean remission. Further research is still needed to assess which clinical remission criterion is best suited to guide treatment.


Disclosure: N. Sundlisater, None; A. Aga, AbbVie, 2, 8, Eli Lilly, 8, MSD, 2, Norwegian Research Council, 2, Norwegian Rheumatism Association, 2, Norwegian South-Eastern Health Region, 2, Norwegian Women's Public Health Association, 2, Novartis, 8, Pfizer, 2, 8, Roche, 2, UCB, 2, 8; U. Sundin, None; H. Hammer, None; T. Uhlig, None; T. Kvien, AbbVie, 2, 8, Biogen, 5, 8, Biogen, Egis, Eli Lilly, Hikma, Mylan, Novartis/Sandoz, Oktal, Hospira/Pfizer, Sanofi and UCB, 5, BMS, 8, Celltrion, 8, Egis, 5, 8, Eli Lilly, 5, 8, Hikma, 5, 8, Hospira/Pfizer, 2, 5, 8, MSD, 2, 8, Mylan, 5, 8, Novartis, 8, Novartis/Sandoz, 5, 8, Oktal, 5, 8, Orion Pharma, 8, Roche, 2, 8, Sandoz, 8, Sanofi, 5, 8, UCB, 5, 8; E. Haavardsholm, AbbVie, 2, 8, Cellgene, 8, Eli Lilly, 8, Janssen, 8, MSD, 2, Norwegian Research Council, 2, Norwegian South-Eastern Health Region, 2, Pfizer, 2, 8, Roche, 2, UCB, 2, 8; S. Lillegraven, AbbVie, 2, MSD, 2, Norwegian Research Council, 2, Norwegian South-Eastern Health Region, 2, Pfizer, 2, Roche, 2, UCB, 2.

To cite this abstract in AMA style:

Sundlisater N, Aga A, Sundin U, Hammer H, Uhlig T, Kvien T, Haavardsholm E, Lillegraven S. Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/limiting-factors-of-reaching-acr-eular-boolean-remission-in-early-ra-patients-treated-according-to-current-recommendations/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/limiting-factors-of-reaching-acr-eular-boolean-remission-in-early-ra-patients-treated-according-to-current-recommendations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences